Morningstar

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy ...

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting – ...
MIT Technology Review

An easier-to-use technique for storing data in DNA is inspired by our cells

Encoding information in DNA has long seemed like a promising way to secure data for the long term, but so far it has required an expert touch. It turns out that you don’t need to be a scientist to ...
TechCrunch

Streamdal wants to bring greater visibility to streaming data architectures

The rise of streaming architectures — frameworks of software components built to ingest and process large volumes of data from multiple sources — is driving the demand for better reliability and ...

Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome

Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...
PharmiWeb

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

– Clinically meaningful gains in multiple measures of neurodevelopment across initial three dose levels, including substantial improvements in cognitive skills by 16 weeks in participants dosed before ...